Sit in on enough Commercial Analytics conversations in Pharma and Biotech right now, and a definitive pattern emerges: everyone has a well-rehearsed point of view on AI. Very few have it driving real-world commercial execution.
Conference stages are crowded with conceptual frameworks. LinkedIn feeds are flooded with predictions. Procurement inboxes are packed with polished pitch decks promising "AI-driven commercial intelligence." And yet ask a simpler operational question: what have you actually deployed, and what happened when it didn't work? The confidence tends to thin out remarkably.
A recent Harvard Business Review piece by John Winsor introduced a distinction that accurately captures this reality, and it is a lens worth using when evaluating any AI advisory, vendor, or your own team on their AI capability.
Thought Leadership vs. Thought Doership
Thought leadership tells you AI will transform Commercial Operations.
Thought doership deploys a functional multi-agent capability to a brand team within 10 days, integrates messy data, and measures the impact.
Thought leadership publishes a framework for AI adoption.
Thought doership restructures how a brand team actually forecasts demand and stands behind the measurable results, not just the framework.
One operates at a safe distance: stages, op-eds, slide decks.
The other operates where it counts: real data, real budget, real commercial decisions riding on the outcome.
The differentiator isn't confidence. It's specificity.
Why this gap matters more in Life Sciences than most industries
Commercial Analytics in Life Sciences isn't a low-stakes category to run basic tech experiments. When a forecasting model or an "AI agent" breaks down under real market complexity, it doesn't just waste a budget cycle. It actively delays critical market adjustments at a moment when the brand team's competitive window is rapidly narrowing.
And the barrier to sounding credible on AI has never been lower. It takes a few well-crafted slides to claim expertise in agentic commercial intelligence. It takes something else entirely to have actually sat inside a brand team's planning cycle long enough to know where the process really breaks.
The differentiator isn't confidence. It's specificity.
Anyone can tell you AI will change how commercial teams operate. Ask them to go one level deeper: what did you build, where did the first version go wrong, what did you change? The answer usually reveals which kind of conversation you're really in.
That's the question worth asking before bringing in any AI or analytics partner right now: not "what's your point of view," but "what have you built, and what happened when it didn't go as planned?" A real practitioner can give you granular specifics: a decision made under uncertainty, a tradeoff, a version that had to be scrapped. A theoretical provider stays safely at 30,000 feet.
Where I land on this
I'll say this as someone who spends a lot of time in exactly these conversations: it's also the standard I try to hold myself to. Fewer decks, more operational capabilities in production, not because reaching production is easy, but because pushing an application hard enough to break is the only way to build something robust enough for a commercial leadership team to genuinely rely on. That's a slower way to demonstrate value, but in my experience, the only way to earn credibility in this industry.
So here's a question to consider, whether you're evaluating a partner or your own team's roadmap: how much time are you spending talking about AI in commercial operations, and how much on building something with it?
If you're in the middle of that evaluation, we'd welcome the opportunity to continue the conversation. Discover how CustomerInsights.AI helps Life Sciences organizations move from AI strategy to production-ready execution.
